We have demonstrated that enzalutamide and USP14 inhibition synergistically inhibit cell viability in breast cancer cells; this combined growth inhibition effect of the two agents is predominantly due to more effective induction of cell cycle arrest and cell apoptosis. The gene discussed is USP14; the disease is breast cancer.